
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Remove Advertising filter Advertising (2)
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Biologicals (2) Apply Biologicals filter
- Remove Blood and blood components filter Blood and blood components (0)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Labelling/Packaging (1) Apply Labelling/Packaging filter
- Legislation (3) Apply Legislation filter
- Listed medicines (2) Apply Listed medicines filter
- Manufacturing (1) Apply Manufacturing filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Medical devices safety (1) Apply Medical devices safety filter
- Remove Medicinal cannabis filter Medicinal cannabis (1)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Remove Prescription medicines filter Prescription medicines (6)
- Scheduling (56) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Blood and blood components filter Blood and blood components
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Advertising filter Advertising
- (-) Remove Prescription medicines filter Prescription medicines
Building a more robust medicine supply - proposals to help prevent, mitigate and manage medicine shortages
Closed on 17 May 2021
Repurposing of prescription medicines
Closed on 30 March 2021
Proposal to remove redundant processes for entering certain formulation information into a therapeutic goods application
Closed on 24 February 2021
Potential reforms to medicinal cannabis manufacturing, labelling and packaging requirement
Closed on 29 January 2021
Boxed Warning guidance
Closed on 31 August 2018
Prescription strong (Schedule 8) opioid use and misuse in Australia – options for a regulatory response
Closed on 2 March 2018
The Scheduling Policy Framework and Advertising of Pharmacist-only medicines (Schedule 3 substances)
Closed on 28 April 2017
Loratadine and desloratadine: proposed advisory statements for medicines
Closed on 7 December 2012
Fexofenadine and loperamide: proposed advisory statements for medicines
Closed on 4 June 2012
Regulation of new excipients in topical non-prescription medicines
Closed on 16 December 2005